A Form FDA 483 tells you what an investigator found during an inspection — a list of factual observations, written on the spot, before anyone at FDA has decided what they add up to. The classification that follows is a separate step, made later, back at the district office, and it’s the part that actually determines what happens next. Two firms can walk away from visibly similar inspections with different classifications, and the difference is rarely visible in the 483 itself.
Why the classification isn’t on the form you got
The 483 is a snapshot from the investigator standing in your facility — the observations are theirs, written under time pressure, before the district office has reviewed anything beyond what they personally saw. The classification comes later, after that district office’s compliance staff reads the full inspection report alongside the firm’s history: prior inspections, prior 483s, whether earlier commitments were actually kept. That’s why the same list of observations can classify differently at two different firms — the 483 only shows what one investigator saw on the days they were there, not what FDA now believes it means for the whole quality system. Reading the 483 itself is a different skill from reading what FDA does with it afterward, and the two are worth keeping separate in your own head.
Reading the database instead of waiting for a letter
For firms that don’t receive a Warning Letter, classification is quiet — no letter, no phone call, just an entry that eventually appears in the record. FDA publishes the search tool as its Inspection Classification Database, and it’s worth checking on your own facility as a matter of practice, not just after a bad inspection: a VAI on file is a real signal even without a Warning Letter attached to it, and a pattern of VAIs across several inspections reads very differently — to FDA, and to anyone doing supplier due diligence on your firm — than one flagged, corrected item followed by a clean record. Reading your own history the way an outside reviewer would is part of the job.
Where people get stuck
Treating a clean 483 as a guaranteed NAI
A 483 with no observations usually classifies NAI, but it isn’t automatic. Investigators can find nothing worth writing up during the visit and still flag something in their fuller report — a discrepancy against a prior inspection, a document reviewed after the closeout meeting. Don’t stop watching once the 483 is in hand.
Assuming VAI means the matter is closed
Voluntary Action Indicated means FDA is choosing not to escalate right now, provided the firm actually makes the correction it committed to. A VAI that goes uncorrected, or the same VAI-level finding showing up again on the next inspection, is exactly the pattern that pushes a future classification toward OAI.
Confusing OAI with a Warning Letter
OAI is FDA’s internal determination that a finding meets the threshold for formal action; a Warning Letter is one of the things that can follow, not a synonym for the classification itself. Some OAI inspections resolve through a follow-up inspection or documented corrective action before a Warning Letter is ever drafted — and some don’t resolve that way at all.
The classification is the part of an inspection a fixed list of observations can’t tell you on its own — the same reason it’s worth reading what a letter actually says rather than treating its title as the whole story. Read your own inspection history the way FDA reads it: as a pattern building across visits, not a series of unconnected events.
Sources & further reading
- FDA — Inspection Classification Database Search fda.gov
- 21 CFR § 820.1 — Quality System Regulation, scope ecfr.gov
- Regulatory Academy — How to Read a Form FDA 483 regulatoryacademy.com
- Regulatory Academy — How to Write an FDA 483 Response regulatoryacademy.com
This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.
